Overview
KJT is a life sciences-focused partner that provides tailored evidence generation and medical communications throughout a product’s lifecycle. Its main function is to help life sciences companies generate the data and messaging needed to support research, regulatory, commercialization, and ongoing medical communications, using customized strategies rather than a one-size-fits-all approach. Unlike firms that offer generic services, KJT aims to be a strategic partner—working closely with clients across the entire lifecycle to align research, evidence, and communication with business goals. The overarching goal is to positively impact its clients’ businesses to improve healthcare globally.
Work here?Claim your company
Simplify's take
What believers are saying
- February 18, 2026 Sparq integration strengthened KJT's connection and prediction capabilities across research workflows.
- April 28, 2026 Jason Solack joined as SVP of Operations, sharpening execution and scaling.
- September 10, 2026 AI-moderated interviewing content positions KJT as a credible generative-AI market research vendor.
What critics are saying
- Accenture, Deloitte, and McKinsey dominate healthcare consulting, squeezing KJT's enterprise deal sizes and pricing.
- DialogueDx faces copycat risk as AI interview tools commoditize by 2027, especially from larger agencies.
- KJT's pharma-client concentration exposes revenue to budget cuts, procurement delays, and one lost anchor account.
What makes KJT unique
- KJT's DialogueDx, updated September 2026, captures exam-room conversations and analyzes them with generative AI.
- KJT combines medical affairs, qualitative research, and commercial strategy for pharma and medtech clients.
- KJT's employee-owned model and 2026 leadership hires support speed, accountability, and domain continuity.
Help us improve and share your feedback! Did you find this helpful?